

Breakthrough vaccine to treat chemo-resistant ovarian cancer

March 8 2007

Cancer Treatment Centers of America announced today its plans to launch a new cancer vaccine therapy that expands treatment options for thousands of women with advanced stage ovarian cancer. This innovative treatment will be offered by Cancer Treatment Centers of America and developed by AVAX Technologies, Inc.

"Cancer Treatment Centers of America's number one priority is to help our patients win the battle against cancer," said Dr. Edgar Staren, Chief Medical Officer of Cancer Treatment Centers of America. "This vaccine therapy represents a promising new chapter in the fight against this devastating disease and brings hope to women everywhere."

The breakthrough treatment method uses the patient's own tumor tissues to create a patient-specific vaccine and is combined with chemotherapy delivered directly into the abdominal cavity.

Ovarian cancer, one of the hardest cancers to detect in the early stages, is a very complex disease that is often resistant to chemotherapy. Cancer Treatment Centers of America will offer this new treatment to patients whose cancer has recurred after chemotherapy.

"To win the fight against cancer, it is absolutely vital we do everything we can to make innovative new treatments like this available to patients as soon as possible," said Dr. Staren. It's inconceivable that treatments like these – that give hope to patients – are often left on the laboratory bench, while cancer patients are told there is nothing more that can be

done for them."

Cancer Treatment Centers of America expects to start treating patients this summer. This promising vaccine technology hopes to eventually be available to treat other forms of cancer including colorectal and lung cancer patients, as well as patients with malignant melanomas.

Source: Cancer Treatment Center of America

Citation: Breakthrough vaccine to treat chemo-resistant ovarian cancer (2007, March 8) retrieved 24 April 2024 from <https://medicalxpress.com/news/2007-03-breakthrough-vaccine-chemo-resistant-ovarian-cancer.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.